ClinicalTrials.gg
RecruitingNCT06989840Updated Oct 21, 2026

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

A Phase 1 interventional study of TVB-3567 and Placebo in Acne, sponsored by Sagimet Biosciences Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sagimet Biosciences Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 21, 2026Study completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Acne Vulgaris with a site in Australia — 2 open to participants now, 2 under way, none of them phase 3. Acne Vulgaris · Australia.

Planned enrollment
7th of 11
152 · median 368
Started
2025
the only one that year
Phase 1
3 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Sagimet Biosciences Inc.

Among the 11 studies in Acne Vulgaris with a site in Australia, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 11 studies in Acne Vulgaris with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acne Vulgaris with a site in Australia, or all of them as a file.
02

Study summary

This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be an open-label, 2-way crossover investigation to assess the effect of food on a single dose of TVB-3567 administered orally in healthy participants. Part C will be a randomized, double-blind, placebo-controlled investigation of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants. Part D will be an open-label investigation of two doses of TVB-3567 across two cohorts, to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants with moderate to severe acne.

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Participants (Parts A, B and C)

  1. Healthy, adult, male or female 18-55 years of age
  2. (BMI) ≥18.0 and ≤32.0 kg/m2
  3. Medically healthy with no medical history
  4. Understands the study procedures in the form (ICF) and willing and able to comply with the protocol

Healthy Participants with Acne (Part D only)

Participants must meet all of the above criteria, as well as the following inclusion criteria to be eligible for participation in the study:

  1. BMI ≥18.0 and ≤37.0 kg/m2.
  2. Must be diagnosed with moderate to severe acne vulgaris

Exclusion criteria

Exclusion Criteria:

Healthy Participants (Parts A, B and C)

  1. History or presence of medical or psychiatric condition or disease
  2. History or presence of or idiosyncratic reaction to the study drug or related compounds including over the counter acne products.
  3. Has a clinically significant ophthalmic examination finding
  4. Female participant of
  5. Unable to refrain from or anticipates the use of:

    • Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements
    • Any topical anti-acne treatment on the face
    • Any drugs known to be moderate or strong inducers of enzymes, BCRP, and/or P gp, including St. John's Wort, beginning 28 days prior to the first dosing.
    • Part C only: Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all-trans retinoic acid.

Healthy Participants with Acne (Part D only)

Participants must not be enrolled if they do not meet any of the above criteria, as well as the following exclusion criteria:

  1. Unable to refrain from or anticipates the use of:

    • Any topical prescription or non-prescription anti-acne cleansers or treatments on the face, beginning 14 days prior to the first dosing.
    • Tretinoins, including tazarotene, adapalene, trifarotene, tretinoin, photodynamic therapy, dermabrasion, or chemical peeling (on the face) beginning 4 weeks prior to the first dosing.
    • Oral retinoid (isotretinoin) therapy beginning 6 months prior to the first dosing.
  2. Significant skin diseases
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Part A (SAD in Healthy Participants)

    Drug: TVB-3567 · Drug: Placebo

  • Experimental
    Part B (Food Effect)

    Drug: TVB-3567

  • Experimental
    Part C (MAD in Healthy Participants)

    Drug: TVB-3567 · Drug: Placebo

  • Experimental
    Part D (MAD in Acne Participants)

    Drug: TVB-3567 · Drug: Placebo

Interventions

  • DrugTVB-3567

    Orally administered capsule

  • DrugPlacebo

    Orally administered capsule

06

What researchers measure

Primary outcomes

  1. Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline to 7 to 8 days after dosing

  2. Part B - Plasma AUC0-t in fasted and fed conditions

    Area under the concentration-time curve from time zero until the last observed concentration

    Time frame: Baseline to Day 4

  3. Part B - Plasma AUC0-inf in fasted and fed conditions

    Area under the concentration-time curve from time zero to infinity

    Time frame: Baseline to Day 4

  4. Part B - Plasma Cmax in fasted and fed conditions

    Maximum concentration measurement in plasma

    Time frame: Baseline to Day 4

  5. Part B - Incidence of adverse events (AEs) and serious adverse events (SAEs) under fasted and fed conditions

    Time frame: Baseline to 7 to 8 days after dosing

  6. Part C - Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline to 13 to 15 days after the last dose

  7. Part D - Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline to 13 to 15 days after the last dose

07

Study locations

3 of 6 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's planned 19 months is above that.

Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 25, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027was Jan 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added. Nucleus Network is now Completed
Show 4 added (4 Australia)
  • Emeritus Research · Botany, Australia
  • The Skin Hospital · Darlinghurst, Australia
  • Emeritus Research · Camberwell, Australia
  • Fremantle Dermatology · Fremantle, Australia
Oct 13, 2026
Study completion
Jan 2027→Feb 2027
Oct 21, 2026
Enrollment
128→152
Oct 21, 2026
Eligibility
3 exclusion criteria added, 3 removed
What changed in the criteria
Exclusion criteria
  • RemovedAny previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all trans retinoic acid.
  • RemovedPhotoelectric therapy, dermabrasion, or chemical peeling
  • RemovedIntra-articular and systemic corticosteroid therapy
  • AddedAny topical prescription or non-prescription anti-acne cleansers or treatments on the face, beginning 14 days prior to the first dosing.
  • AddedTretinoins, including tazarotene, adapalene, trifarotene, tretinoin, photodynamic therapy, dermabrasion, or chemical peeling (on the face) beginning 4 weeks prior to the first dosing.
  • AddedOral retinoid (isotretinoin) therapy beginning 6 months prior to the first dosing.
Oct 21, 2026
Show all 2 updates
  1. Oct 21, 2026
    Study completion Jan 2027→Feb 2027
    Enrollment 128→152
    Eligibility 3 exclusion criteria added, 3 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedAny previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all trans retinoic acid.
    • RemovedPhotoelectric therapy, dermabrasion, or chemical peeling
    • RemovedIntra-articular and systemic corticosteroid therapy
    • AddedAny topical prescription or non-prescription anti-acne cleansers or treatments on the face, beginning 14 days prior to the first dosing.
    • AddedTretinoins, including tazarotene, adapalene, trifarotene, tretinoin, photodynamic therapy, dermabrasion, or chemical peeling (on the face) beginning 4 weeks prior to the first dosing.
    • AddedOral retinoid (isotretinoin) therapy beginning 6 months prior to the first dosing.
    + 2 other changes: description and design details
  2. Oct 13, 2026
    4 sites added. Nucleus Network is now Completed
    Show 4 added (4 Australia)
    • Emeritus Research · Botany, Australia
    • The Skin Hospital · Darlinghurst, Australia
    • Emeritus Research · Camberwell, Australia
    • Fremantle Dermatology · Fremantle, Australia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06989840
Lead sponsor
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jun 3, 2025
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Study Director
Contact
SB3567-CLIN-001@sagimet.com
(650) 561-8600

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion